ABSTRACT
Invasive fungal infections (IFI) have become a major cause of morbidity and mortality in immunocompromised patients (1-5). The incidence and the mortality rate varies among the different underlying diseases, with relapsed acute leukemia patients and those undergoing allogeneic hematopoietic stem cell transplantation having the highest risk, followed by solid organ transplant recipients, critically ill surgical patients, and premature neonates (6,7). Candida-and Aspergillus species still account for the vast majority of documented infections, but recent epidemiological surveys have revealed the emergence of previously uncommon pathogens that are often less susceptible to conventional antifungal agents (8,9). This shift will have an impact on the choice of appropriate agents for empirical antifungal therapy.
